Blumethal H P, Ryan J R, Jain A K, McMahon F G
Lipids. 1977 Jan;12(1):44-8. doi: 10.1007/BF02532970.
Nineteen patients with type II, III, IV, or V hyperlipoproteinemia received gemcadiol (2,2,9,9,-tetramethyl-1,10-decanediol) in daily doses between 1.2 and 2 g. The patients were hospitalized for dose titration and then followed as outpatients on appropriate doses of gemcadiol. In Type II hyperlipoproteinemia, serum cholesterol was lowered by an average of 24%. The serum triglycerides in Type IV hyperlipoproteinemia decreased by an average of 51%. Serum uric acid was not altered. There were no changes of subjective feelings or of clinical or laboratory findings, including creatine phosphokinase. This study indicates that gemcadiol is an effective antilipemic agent that is very well tolerated.
19例II型、III型、IV型或V型高脂蛋白血症患者接受了吉美二醇（2,2,9,9 - 四甲基 - 1,10 - 癸二醇）治疗，日剂量为1.2至2克。患者住院进行剂量滴定，然后作为门诊患者接受适当剂量的吉美二醇治疗。在II型高脂蛋白血症中，血清胆固醇平均降低了24%。IV型高脂蛋白血症患者的血清甘油三酯平均降低了51%。血清尿酸未发生改变。主观感受、临床或实验室检查结果（包括肌酸磷酸激酶）均无变化。本研究表明，吉美二醇是一种耐受性良好的有效抗脂药。
